Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1084/jem.20211818 http://scihub22266oqcxt.onion/10.1084/jem.20211818 34757384!8590200!34757384     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Exp+Med 2022 ; 219 (1): ä Nephropedia Template TP {{tp|p=34757384|t=2022. A stem-loop RNA RIG-I agonist protects against acute and chronic SARS-CoV-2 infection in mice |pdf=|usr=}}{{34757384}} gab.com Text A stem-loop RNA RIG-I agonist protects against acute and chronic SARS-CoV-2 infection in mice JO: J Exp Med http://www.kidney.de/pget.php?&tw=1&pmid=34757384 #FOAvip As SARS-CoV-2 continues to cause morbidity and mortality around the world, there is an urgent need for the development of effective medical countermeasures. Here, we assessed the antiviral capacity of a minimal RIG-I agonist, stem-loop RNA 14 (SLR14), in viral control, disease prevention, post-infection therapy, and cross-variant protection in mouse models of SARS-CoV-2 infection. A single dose of SLR14 prevented viral infection in the lower respiratory tract and development of severe disease in a type I interferon (IFN-I)-dependent manner. SLR14 demonstrated remarkable prophylactic protective capacity against lethal SARS-CoV-2 infection and retained considerable efficacy as a therapeutic agent. In immunodeficient mice carrying chronic SARS-CoV-2 infection, SLR14 elicited near-sterilizing innate immunity in the absence of the adaptive immune system. In the context of infection with variants of concern (VOCs), SLR14 conferred broad protection against emerging VOCs. These findings demonstrate the therapeutic potential of SLR14 as a host-directed, broad-spectrum antiviral for early post-exposure treatment and treatment of chronically infected immunosuppressed patients. Twit Text FOAVip A stem-loop RNA RIG-I agonist protects against acute and chronic SARS-CoV-2 infection in mice ????J Exp Med http://www.kidney.de/pget.php?&tw=1&pmid=34757384 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34757384 #FOAvip English Wikipedia <ref>{{Cite pmid|34757384}}</ref> A stem-loop RNA RIG-I agonist protects against acute and chronic SARS-CoV-2 infection in mice #MMPMID34757384 Mao T; Israelow B; Lucas C; Vogels CBF; Gomez-Calvo ML; Fedorova O; Breban MI; Menasche BL; Dong H; Linehan M; Wilen CB; Landry ML; Grubaugh ND; Pyle AM; Iwasaki A J Exp Med 2022[Jan]; 219 (1): ä PMID34757384show ga As SARS-CoV-2 continues to cause morbidity and mortality around the world, there is an urgent need for the development of effective medical countermeasures. Here, we assessed the antiviral capacity of a minimal RIG-I agonist, stem-loop RNA 14 (SLR14), in viral control, disease prevention, post-infection therapy, and cross-variant protection in mouse models of SARS-CoV-2 infection. A single dose of SLR14 prevented viral infection in the lower respiratory tract and development of severe disease in a type I interferon (IFN-I)-dependent manner. SLR14 demonstrated remarkable prophylactic protective capacity against lethal SARS-CoV-2 infection and retained considerable efficacy as a therapeutic agent. In immunodeficient mice carrying chronic SARS-CoV-2 infection, SLR14 elicited near-sterilizing innate immunity in the absence of the adaptive immune system. In the context of infection with variants of concern (VOCs), SLR14 conferred broad protection against emerging VOCs. These findings demonstrate the therapeutic potential of SLR14 as a host-directed, broad-spectrum antiviral for early post-exposure treatment and treatment of chronically infected immunosuppressed patients. |*COVID-19 Drug Treatment[MESH] |Animals[MESH] |Antiviral Agents/*pharmacology[MESH] |COVID-19/metabolism[MESH] |Disease Models, Animal[MESH] |Immunity, Innate/drug effects[MESH] |Interferon Type I/metabolism[MESH] |Mice[MESH] |Mice, Inbred BALB C[MESH] |RNA/*metabolism[MESH]A stem-loop RNA RIG-I agonist protects against acute and chronic SARS-(epmc).pdf DeepDyve Pubget Overpricing